|Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.||Pres, CEO & Director||956.8k||N/A||1961|
|Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.||Founder & Director||526.39k||N/A||1959|
|Mr. John J. Canepa||Chief Financial Officer||449.12k||N/A||1956|
|Ms. Carrie Smith Cox||Special Advisor to the CEO||56.25k||N/A||1958|
|Dr. Seshu Tyagarajan Ph.D.||Chief Technical & Devel. Officer||N/A||N/A||N/A|
|Dr. Francesca Barone M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1978|
|Ms. Ileen B. Winick||Chief People Officer||N/A||N/A||N/A|
|Ms. Susan Stewart J.D.||Chief Regulatory Officer||N/A||N/A||1962|
|Mr. Nathan Caffo||Chief Bus. Officer||N/A||N/A||1969|
|Mr. Stephen Charles Rocamboli||Sec.||N/A||N/A||1972|
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.